The cloning, overexpression, purification, crystallization and preliminary crystallographic analysis of the C-terminal domain of prostate apoptosis response-4 protein (Par-4) are presented.
Keywords: Par-4, coiled coil, leucine zipper
Abstract
Prostate apoptosis response-4 protein is an intrinsically disordered pro-apoptotic protein with tumour suppressor function. Par-4 is known for its selective induction of apoptosis in cancer cells only and its ability to interact with various apoptotic proteins via its C-terminus. Par-4, with its unique function and various interacting partners, has gained importance as a potential target for cancer therapy. The C-terminus of the rat homologue of Par-4 was crystallized and a 3.7 Å resolution X-ray diffraction data set was collected. Preliminary data analysis shows the space group to be P41212. The unit-cell parameters are a = b = 115.351, c = 123.663 Å, α = β = γ = 90°.
1. Introduction
Prostate apoptosis response-4 protein (Par-4) or PRKC apoptosis WT1 regulator protein (PAWR) is a pro-apoptotic tumour suppressor protein (Zhao & Rangnekar, 2008 ▶), the gene for which was found during a screen for genes induced by effectors of apoptosis in prostate cancer cell lines by differential hybridization (Sells et al., 1994 ▶). It is a multi-domain protein whose expression is ubiquitous (Boghaert et al., 1997 ▶) and it is evolutionarily conserved in vertebrates (Boghaert et al., 1997 ▶; Libich et al., 2009 ▶). Its N-terminus contains nuclear localization sequences (NLS1 and NLS2) and the unique SAC domain (selective for apoptosis of cancer cells), which is the minimum required fragment necessary for inducing apoptosis selectively in cancer cells (El-Guendy et al., 2003 ▶). The C-terminus (amino acids 258–332) of Par-4, which shares homology with the death domains of other apoptotic proteins (Díaz-Meco et al., 1996 ▶), includes a putative leucine-zipper (LZ) domain (amino acids 290–332; Sells et al., 1997 ▶) with heptad repeats (abcdefg)6 with hydrophobic amino acids at position a and predominantly leucines at position d (Sells et al., 1997 ▶). Par-4 is known to homodimerize (Díaz-Meco et al., 1996 ▶) and has been shown to interact with various proteins such as Wilms’ tumour suppresor WT1 (Johnstone et al., 1996 ▶), ζPKC and λ/ιPKC (Díaz-Meco et al., 1996 ▶), Dlk/ZIP kinase (Page et al., 1999 ▶), atypical PKCs and p62 (Chang et al., 2002 ▶), THAP (Roussigne et al., 2003 ▶), AATF (Guo & Xie, 2004 ▶), Akt1/protein kinase B (Goswami et al., 2005 ▶), Amida (Boosen et al., 2005 ▶), dopamine D2 receptor (Park et al., 2005 ▶), β-site APP-cleaving enzyme-1 (Xie & Guo, 2005 ▶), E2F1 (Lu et al., 2008 ▶) and topoisomerase 1 (Goswami et al., 2008 ▶) via its LZ domain. The LZ domain has been shown to be natively unfolded at physiological pH and temperature, whereas the coiled coil becomes favoured at low pH and low temperature (Dutta et al., 2001 ▶).
Structural analysis of functional domains of Par-4 will provide insights into the mechanism of its interactions and selective induction of apoptosis. In the current report, the crystallization of the C-terminal 240–332 amino acids, referred to as the C-terminal domain, which includes the phosphorylation site of Akt (Ser249; Goswami et al., 2005 ▶), the death-domain homologous sequence, the coiled-coil region (254–332) and the LZ domain (292–330), is presented.
2. Materials and methods
2.1. Cloning, expression and purification of the C-terminal domain of Par-4
The DNA sequence corresponding to the C-terminal amino acids 240–332 of rat Par-4 (UniProt accession No. Q62627) was amplified from the Par-4 full-length plasmid 091199A17 (Eidhoff, 2000 ▶) by polymerase chain reaction and cloned into pET-11a vector using NdeI and BamHI restriction sites along with an N-terminal Strep-tag II. The primer details are shown in Table 1 ▶.
Table 1. DNA source and protein information for the C-terminal domain of Par-4.
NdeI and BamHI restriction sites are shown in italic for the respective primers and the Strep-Tag II sequence is shown underlined. The Strep-Tag II in the N-terminus of the protein sequence is shown underlined.
| Source organism | Rattus norvegicus |
| DNA source | Par-4 full-length plasmid 091199A17 (Eidhoff, 2000 ▶) |
| Forward primer | GCGCATATGGCTAGCTGGAGCCACCCGCAGTTCGAGAAGGCGGGCTTCAGTAGACACAACAGAGATACC |
| Reverse primer | CCTGGATCCCTACCTTGTCAGCTGCCCAAC |
| Expression vector | pET-11a |
| Expression host | RIL/RP strains of E. coli BL21 (DE3) |
| Complete amino-acid sequence of the construct produced | MASWSHPQFEKAGFSRHNRDTSAPANFASSSTLEKRIEDLEKEVLRERQENLRLTRLMQDKEEMIGKLKEEIDLLNRDLDDMEDENEQLKQENKTLLKVVGQLTR |
The C-terminal domain transformants of RIL or RP strains of Escherichia coli BL21(DE3) were selected on an LB–agar plate with 200 µg ml−1 ampicillin. A primary culture of DYT medium supplemented with 200 µg ml−1 ampicillin, which was also maintained in the secondary culture, was set up and allowed to grow overnight at 37°C and 200 rev min−1. The secondary culture, with 750 ml DYT medium per 2 l baffled flask, was inoculated with the primary culture and allowed to grow at 37°C and 110 rev min−1. When the OD600 of the culture was 0.6–0.8, overexpression of the C-terminal domain was induced with 1 mM isopropyl β-d-1-thiogalactopyranoside (IPTG) and continued for 4 h. The culture was harvested at 4000g for 20 min at 4°C. The cell pellet was resuspended in lysis buffer (50 mM Tris buffer pH 7.5, 200 mM MgCl2) with protease inhibitor (Complete EDTA-free, Roche) and 15 µg ml−1 deoxyribonuclease I (5 g of cell pellet in 50 ml of lysis buffer) and passed through an EmulsiFlex-C3 cell disruptor two to three times with a pressure of 103–152 MPa. The lysate was clarified by centrifugation at 57 000g for 45 min at 4°C and the supernatant was loaded onto a gravity-flow column with Strep-Tactin Superflow high-capacity resin pre-equilibrated with five bed volumes of equilibration buffer (50 mM Tris buffer pH 7.5 containing 200 mM MgCl2). The column was washed with four to five bed volumes of the equilibration buffer and the C-terminal domain was eluted by lowering the pH with elution buffer (50 mM potassium phosphate buffer pH 4). The protein fractions were pooled, concentrated and filtered through a 0.22 µm filter. The protein sample was loaded onto a HiLoad 16/60 Superdex 75 gel-filtration prep-grade column pre-equilibrated with the elution buffer. Protein fractions corresponding to the peak were pooled and concentrated.
2.2. Crystallization
The freshly purified protein sample at a concentration of 40–45 mg ml−1 was used for setting up crystallization plates. Crystallization experiments were performed with 100 mM sodium citrate buffer pH 5.9 with 17–42% tert-butanol. Different ratios of protein to reservoir buffer were tried. The crystallization plates were incubated at 22°C.
2.3. Data collection and processing
Perfluoropolyether (PFO) or LV CryoOil (LVCO-1) was overlaid on the sitting drop immediately after opening the crystallization experiment. Crystals were picked with cryoloops and soaked in PFO before flash-cooling in a nitrogen cryo-stream at −173°C. Data collection was performed at −173°C on the ID23-1 beamline at the European Synchrotron Radiation Facility (ESRF), Grenoble, France. Data were processed with XDS (Kabsch, 2010 ▶) and analyzed using POINTLESS (Evans, 2006 ▶, 2011 ▶) and the phenix.xtriage module of PHENIX (Adams et al., 2010 ▶).
3. Results and discussion
3.1. Expression and purification of C-terminal domain of Par-4
The C-terminal domain of Par-4 was overexpressed yielding 1.5–2.0 mg purified protein per 1 g of cell pellet. The purified C-terminal domain of Par-4 was analyzed by SDS–PAGE, which shows a single band of protein (Fig. 1 ▶ a). The molecular weight of the C-terminal domain estimated from SDS–PAGE was 12.2 kDa, which is in good agreement with the value given by mass-spectrometric analysis, i.e. 12.26 kDa (data not shown). The SEC (size-exclusion chromatography) profile shows that the protein elutes with an apparent molecular weight of 95 kDa, which could indicate an octamer (12.2 kDa × 8 = 97.6 kDa; data not shown). Considering the fact that the SEC separation is based on Stokes radii (Hong et al., 2012 ▶) and the oligomer is predicted to be an anisotropic molecule, there could be an offset in the estimated molecular weight of the oligomer, which was based on a calibration made using standard globular proteins. Fig. 1 ▶(b) shows that the protein sample after affinity purification is DNA-free.
Figure 1.

(a) SDS–PAGE analysis of purification of the C-terminal domain of Par-4. Lane 1, PageRuler Prestained Protein Ladder (labelled in kDa); lane 2, cell lysate; lane 3, flowthrough; lane 4, wash; lanes 5–8, elutions 1–4, respectively; lane 9, pooled C-terminal domain of Par-4; lane 10, C-terminal domain of Par-4 before loading onto a gel-filtration column. (b) Agarose gel electrophoresis of samples from the purification of the C-terminal domain of Par-4. Lane 1, cell lysate 1; lane 2, cell lysate 2; lane 3, flowthrough 1; lane 4, flowthrough 2; lane 5, C-terminal domain; lane 6, 100 bp DNA Ladder (NEB) (labelled in base pairs).
3.2. Crystallization
An initial crystallization condition was obtained by screening with commercially available crystallization screens from Hampton Research and Rigaku Reagents (Crystal Screen, Crystal Screen 2, Wizard Classic 1 and 2, and Wizard Cryo 1 and 2). Crystal Screen 2 gave a crystal in the crystallization condition No. 17, i.e. 0.1 M sodium citrate tribasic dihydrate pH 5.6, 35%(v/v) tert-butanol. A grid screen for pH and tertiary butanol concentration gave an improved crystallization condition (Kubicek, 2005 ▶). The improved crystallization condition for the C-terminal domain of Par-4 consisted of 37–42% tert-butanol, 100 mM sodium citrate/citric acid pH 5.9. Immediately after the addition of crystallization buffer protein precipitation was observed, but the sample usually cleared within an hour. In some experiments the protein remained in the precipitated form. Phase transformation of precipitated protein to a gel-like phase was observed when a 24-well plate with 1 ml reservoir buffer and 7–10 µl sitting-drop volume was used. For the smaller sitting-drop volumes of 0.6–1.5 µl the gel-like phase was observed only infrequently.
Crystals appeared randomly from the clear crystallization droplet as well as from the gel-like phase within a time range of 3 d to a couple of weeks. The protein mostly formed tetragonal bipyramidal crystals (Fig. 2 ▶). Crystallization details are given in Table 2 ▶.
Figure 2.

Crystal of the C-terminal domain of Par-4 used for data collection.
Table 2. Crystallization of the C-terminal domain of Par-4.
| Method | Vapour diffusion, sitting drop |
| Plate type | 96-well |
| Temperature (°C) | 22.15 |
| Protein concentration (mg ml−1) | 40 |
| Buffer composition of protein solution | 50 mM potassium phosphate pH 4.0 |
| Composition of reservoir solution | 37–42% tert-butanol, 100 mM sodium citrate pH 5.9 |
| Volume and ratio of drop | 1.4 µl, 1:1.3 protein:crystallization buffer |
| Volume of reservoir (µl) | 70 |
3.3. Crystal cooling and data collection
The obtained crystals are very sensitive with respect to the loss of volatile crystallization buffer components upon opening the experiment. After opening the experiment under the microscope the crystals could be seen to move before collapsing to precipitate within 5–10 s. The diffraction of the crystals of the C-terminal domain of Par-4 was usually limited to medium resolution, extending to around 3.7 Å resolution at −173°C. Including different concentrations of a cryoprotectant, e.g. 2-methyl-2,4-pentanediol (MPD), in the crystallization buffer or soaking the crystal in a cryoprotectant was not helpful as the time required for crystal collection was sufficient for the crystal to be destroyed. Overlaying PFO on the sitting drop immediately after opening the experiment helped to slow down the evaporation. Crystals were picked up and immersed in PFO before plunging into the cryostream. This method of cooling helped in obtaining the diffraction data beyond 3.7 Å resolution (Fig. 3 ▶).
Figure 3.
X-ray diffraction image of the C-terminal domain of Par-4 with resolution rings.
The data exhibited severe anisotropy as indicated by the Diffraction Anisotropy Server at UCLA MBI (Strong et al., 2006 ▶), as a consequence of which the data had to be cut at 3.7 Å resolution [for the 3.6 Å shell 〈I/σ(I)〉 = 5.24 and R meas = 46.6%]. Data analysis (Table 3 ▶) predicted the best possible space group to be P41212. No twin laws are possible for this space group and the data statistics are shown in Table 3 ▶. Unit-cell content analysis suggested the asymmetric unit contains seven molecules (solvent content of 51.1% and V M = 2.51 Å3 Da−1; Matthews, 1968 ▶). The presence of an odd number of molecules in the asymmetric unit cell in spite of dimeric coiled-coil formation indicates that the true number could be either six or eight. It could also be possible with three dimers and a crystallographic dimer. Selenomethionine labelling of the protein is aimed at obtaining experimental phases.
Table 3. Data collection and processing.
Values in parentheses are for the outer shell.
| Diffraction source | Synchrotron |
| Wavelength (Å) | 0.972400 |
| Temperature (°C) | −173 |
| Detector | ADSC |
| Crystal-to-detector distance (mm) | 458.842 |
| Rotation range per image (°) | 2.0 |
| Total rotation range (°) | 182 |
| Exposure time per image (s) | 0.9 |
| Space group | P41212 |
| a, b, c (Å) | 115.351, 115.351, 123.663 |
| α, β, γ (°) | 90.000, 90.000, 90.000 |
| Mosaicity (°) | 0.185 |
| Resolution range (Å) | 49.27–3.71 |
| Total No. of reflections | 130664 |
| No. of unique reflections | 9350 |
| Completeness (%) | 99.7 (99.4) |
| 〈I/σ(I)〉 | 27.56 (10.57) |
| R meas (%) | 6.4 (27.6) |
| Overall B factor from Wilson plot (Å2) | 90.178 |
| Twinning analysis | |
| Statistics independent of twin laws | |
| 〈I 2〉/〈I〉2 | 2.204 |
| 〈F〉2/〈F 2〉 | 0.775 |
| 〈|E 2 − 1|〉 | 0.759 |
| 〈|L|〉, 〈L 2〉 | 0.476, 0.307 |
| Multivariate Z-score L-test | 1.082 |
Acknowledgments
We are grateful to the local contact at the ESRF for providing assistance in using beamline ID23-1.
References
- Adams, P. D. et al. (2010). Acta Cryst. D66, 213–221.
- Boghaert, E. R., Sells, S. F., Walid, A. J., Malone, P., Williams, N. M., Weinstein, M. H., Strange, R. & Rangnekar, V. M. (1997). Cell Growth Differ. 8, 881–890. [PubMed]
- Boosen, M., Vetterkind, S., Koplin, A., Illenberger, S. & Preuss, U. (2005). Exp. Cell Res. 311, 177–191. [DOI] [PubMed]
- Chang, S., Kim, J. H. & Shin, J. (2002). FEBS Lett. 510, 57–61. [DOI] [PubMed]
- Díaz-Meco, M. T., Municio, M. M., Frutos, S., Sanchez, P., Lozano, J., Sanz, L. & Moscat, J. (1996). Cell, 86, 777–786. [DOI] [PubMed]
- Dutta, K., Alexandrov, A., Huang, H. & Pascal, S. M. (2001). Protein Sci. 10, 2531–2540. [DOI] [PMC free article] [PubMed]
- Eidhoff, U. B. (2000). PhD thesis, Heinrich-Heine-Universität, Düsseldorf, Germany.
- El-Guendy, N., Zhao, Y., Gurumurthy, S., Burikhanov, R. & Rangnekar, V. M. (2003). Mol. Cell. Biol. 23, 5516–5525. [DOI] [PMC free article] [PubMed]
- Evans, P. (2006). Acta Cryst. D62, 72–82. [DOI] [PubMed]
- Evans, P. R. (2011). Acta Cryst. D67, 282–292. [DOI] [PMC free article] [PubMed]
- Goswami, A., Burikhanov, R., de Thonel, A., Fujita, N., Goswami, M., Zhao, Y., Eriksson, J. E., Tsuruo, T. & Rangnekar, V. M. (2005). Mol. Cell, 20, 33–44. [DOI] [PubMed]
- Goswami, A., Qiu, S., Dexheimer, T. S., Ranganathan, P., Burikhanov, R., Pommier, Y. & Rangnekar, V. M. (2008). Cancer Res. 68, 6190–6198. [DOI] [PMC free article] [PubMed]
- Guo, Q. & Xie, J. (2004). J. Biol. Chem. 279, 4596–4603. [DOI] [PubMed]
- Hong, P., Koza, S. & Bouvier, E. S. (2012). J. Liq. Chromatogr. Relat. Technol. 35, 2923–2950. [DOI] [PMC free article] [PubMed]
- Johnstone, R. W., See, R. H., Sells, S. F., Wang, J., Muthukkumar, S., Englert, C., Haber, D. A., Licht, J. D., Sugrue, S. P., Roberts, T., Rangnekar, V. M. & Shi, Y. (1996). Mol. Cell. Biol. 16, 6945–6956. [DOI] [PMC free article] [PubMed]
- Kabsch, W. (2010). Acta Cryst. D66, 125–132. [DOI] [PMC free article] [PubMed]
- Kubicek, J. (2005). PhD thesis, Heinrich-Heine-Universität Düsseldorf, Germany.
- Libich, D. S., Schwalbe, M., Kate, S., Venugopal, H., Claridge, J. K., Edwards, P. J., Dutta, K. & Pascal, S. M. (2009). FEBS J. 276, 3710–3728. [DOI] [PubMed]
- Lu, C., Chen, J.-Q., Zhou, G.-P., Wu, S.-H., Guan, Y.-F. & Yuan, C.-S. (2008). Nucleic Acids Res. 36, 5021–5032. [DOI] [PMC free article] [PubMed]
- Matthews, B. W. (1968). J. Mol. Biol. 33, 491–497. [DOI] [PubMed]
- Page, G., Kögel, D., Rangnekar, V. & Scheidtmann, K. H. (1999). Oncogene, 18, 7265–7273. [DOI] [PubMed]
- Park, S. K., Nguyen, M. D., Fischer, A., Luke, M. P.-S., Affar, E. B., Dieffenbach, P. B., Tseng, H.-C., Shi, Y. & Tsai, L.-H. (2005). Cell, 122, 275–287. [DOI] [PubMed]
- Roussigne, M., Cayrol, C., Clouaire, T., Amalric, F. & Girard, J.-P. (2003). Oncogene, 22, 2432–2442. [DOI] [PubMed]
- Sells, S. F. et al. (1997). Mol. Cell. Biol. 17, 3823–3832. [DOI] [PMC free article] [PubMed]
- Sells, S. F., Wood, D. P. Jr, Joshi-Barve, S. S., Muthukumar, S., Jacob, R. J., Crist, S. A., Humphreys, S. & Rangnekar, V. M. (1994). Cell Growth Differ. 5, 457–466. [PubMed]
- Strong, M., Sawaya, M. R., Wang, S., Phillips, M., Cascio, D. & Eisenberg, D. (2006). Proc. Natl Acad. Sci. USA, 103, 8060–8065. [DOI] [PMC free article] [PubMed]
- Xie, J. & Guo, Q. (2005). J. Biol. Chem. 280, 13824–13832. [DOI] [PubMed]
- Zhao, Y. & Rangnekar, V. M. (2008). Cancer Biol. Ther. 7, 1867–1874. [DOI] [PMC free article] [PubMed]

